These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31709029)

  • 1. Strong dose response after immunotherapy with PQ grass using conjunctival provocation testing.
    Zielen S; Kuna P; Aberer W; Lassmann S; Pfaar O; Klimek L; Wade A; Kluehr K; Raab J; Wessiepe D; Lee D; Kramer MF; Gunawardena K; Higenbottam T; Heath MD; Skinner MA; de Kam PJ
    World Allergy Organ J; 2019 Nov; 12(11):100075. PubMed ID: 31709029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptome analysis and safety profile of the early-phase clinical response to an adjuvanted grass allergoid immunotherapy.
    Starchenka S; Heath MD; Lineberry A; Higenbottam T; Skinner MA
    World Allergy Organ J; 2019 Nov; 12(11):100087. PubMed ID: 31768216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy.
    Worm M; Higenbottam T; Pfaar O; Mösges R; Aberer W; Gunawardena K; Wessiepe D; Lee D; Kramer MF; Skinner M; Lees B; Zielen S
    Allergy; 2018 Sep; 73(9):1812-1822. PubMed ID: 29779247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy.
    de Kam PJ; Zielen S; Bernstein JA; Berger U; Berger M; Cuevas M; Cypcar D; Fuhr-Horst A; Greisner WA; Jandl M; Laßmann S; Worm M; Matz J; Sher E; Smith C; Steven GC; Mösges R; Shamji MH; DuBuske L; Borghese F; Oluwayi K; Zwingers T; Seybold M; Armfield O; Heath MD; Hewings SJ; Kramer MF; Skinner MA
    Allergy; 2023 Oct; 78(10):2756-2766. PubMed ID: 37366581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world study.
    Florido-López JF; Andreu-Balaguer C; Escudero C; Seoane-Rodríguez M; Hernández M; Navarro-Seisdedos LÁ; Torrecillas-Toro M; Anton-Girones M; Herrero-Lifona L; Brugaletta D; Macías J; Pineda R; Lara MÁ; López-Caballero J; Rojas MJ
    World Allergy Organ J; 2020 Dec; 13(12):100487. PubMed ID: 33376572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy.
    Starchenka S; Oluwayi K; Heath M; Armfield O; Shamji M; Layhadi J; Lis K; Cadavez L; Rusyn O; Skinner M; De Kam PJ
    Clin Exp Allergy; 2024 Feb; 54(2):130-142. PubMed ID: 38169056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-response relationship of a new Timothy grass pollen allergoid in comparison with a 6-grass pollen allergoid.
    Pfaar O; Hohlfeld JM; Al-Kadah B; Hauswald B; Homey B; Hunzelmann N; Schliemann S; Velling P; Worm M; Klimek L
    Clin Exp Allergy; 2017 Nov; 47(11):1445-1455. PubMed ID: 28696503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.
    Patel P; Holdich T; Fischer von Weikersthal-Drachenberg KJ; Huber B
    J Allergy Clin Immunol; 2014 Jan; 133(1):121-9.e1-2. PubMed ID: 23870670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early nonreactivity in the conjunctival provocation test predicts beneficial outcome of sublingual immunotherapy.
    Köther J; Mandl A; Allekotte S; Astvatsatourov A; Chwieralski J; Liedtke JP; Pieper-Fürst U; Raskopf E; Shah-Hosseini K; Mösges R
    Clin Transl Allergy; 2018; 8():28. PubMed ID: 29997888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy.
    Mösges R; Kasche EM; Raskopf E; Singh J; Sohlich L; Astvatsatourov A; Shah-Hosseini K; Pirotton S; Haazen L; Durham SR; Legon T; Zadoyan G; Shamji MH
    Allergy; 2018 Apr; 73(4):896-904. PubMed ID: 29150857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial.
    Mösges R; Bachert C; Panzner P; Calderon MA; Haazen L; Pirotton S; Wathelet N; Durham SR; Bonny MA; Legon T; von Frenckell R; Pfaar O; Shamji MH
    Allergy; 2018 Sep; 73(9):1842-1850. PubMed ID: 29512827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.
    Winther L; Malling HJ; Mosbech H
    Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
    Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intradermal Phleum pratense allergoid immunotherapy. Double-blind, randomized, placebo-controlled trial.
    Sola Martínez FJ; Barranco Jiménez RM; Martín García C; Senent Sánchez C; Blanco Guerra C; Fernández-Rivas M; Vega Castro A; Dávila González I; Carbonell Martínez A; Panizo Bravo C; Gómez Torrijos E; Rodríguez Gil D; Palacios Peláez R
    Clin Exp Allergy; 2020 Dec; 50(12):1352-1361. PubMed ID: 32946612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.
    Niederberger V; Neubauer A; Gevaert P; Zidarn M; Worm M; Aberer W; Malling HJ; Pfaar O; Klimek L; Pfützner W; Ring J; Darsow U; Novak N; Gerth van Wijk R; Eckl-Dorna J; Focke-Tejkl M; Weber M; Müller HH; Klinger J; Stolz F; Breit N; Henning R; Valenta R
    J Allergy Clin Immunol; 2018 Aug; 142(2):497-509.e9. PubMed ID: 29361332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet.
    Nelson H; Lehmann L; Blaiss MS
    Curr Med Res Opin; 2012 Jun; 28(6):1043-51. PubMed ID: 22502864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study.
    Leynadier F; Banoun L; Dollois B; Terrier P; Epstein M; Guinnepain MT; Firon D; Traube C; Fadel R; André C
    Clin Exp Allergy; 2001 Jul; 31(7):988-96. PubMed ID: 11467988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen.
    DuBuske LM; Frew AJ; Horak F; Keith PK; Corrigan CJ; Aberer W; Holdich T; von Weikersthal-Drachenberg KJ
    Allergy Asthma Proc; 2011; 32(3):239-47. PubMed ID: 21535913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high-dose, depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy has a favourable efficacy/safety ratio.
    Pfaar O; Sager A; Mösges R; Worm M
    Clin Transl Allergy; 2023 Nov; 13(11):e12315. PubMed ID: 38006380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.